Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Leap Therapeutics, Inc. under the historical ticker LPTX provides official documentation of the company’s evolution into Cypherpunk Technologies Inc. and its dual focus on oncology therapeutics and a Zcash-centered digital asset treasury strategy. Forms 8-K detail key events such as the October 2025 private placement led by Winklevoss Capital, adoption of the digital asset treasury strategy, and subsequent name change to Cypherpunk Technologies Inc., along with the planned shift to trading under the symbol CYPH on the Nasdaq Capital Market.
Regulatory reports describe capital markets transactions, including the issuance of common stock, pre-funded warrants, and common warrants, registration rights agreements, and a controlled equity offering sales agreement that allows at-the-market issuances of common stock. Other filings outline Nasdaq bid price deficiency notices, the grant of an additional compliance period, and the company’s consideration of a reverse stock split to address listing standards.
Filings also cover corporate governance and compensation, such as consulting and employment agreements with new digital asset–focused leadership, equity incentive awards in the form of restricted stock units, and board expansion and nomination rights for the lead investor. The definitive proxy statement for a special meeting explains proposals to increase authorized shares, authorize a reverse stock split range, adopt a new equity incentive plan, and approve additional share issuance under the private placement warrants.
For those analyzing the oncology side of the business, 8-Ks and related exhibits reference the wind-down of the DeFianCe clinical trial, reductions in research and development activities, and the exploration of strategic alternatives for sirexatamab and FL-501. On Stock Titan, these filings are paired with AI-powered summaries that help interpret complex agreements, capital structure changes, and disclosure language, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and proxy materials for the issuer formerly known as Leap Therapeutics are quickly accessible.
Cypherpunk Technologies Inc. (CYPH)Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.
Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.
Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.
Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.
Cypherpunk Technologies Inc. (CYPH)11/11/2025, Director and officer Douglas E. Onsi received 2,087,287 restricted stock units (RSUs) under the company’s 2016 Equity Incentive Plan for $0 consideration.
The RSUs vest as follows: 12/36th on October 8, 2026 and 1/36th on the 8th day of each month thereafter, subject to continued service. Vested RSUs will be settled in common stock at the earliest of: the first payroll period after the end of the reporting person’s employment or service, the first payroll period on or after the 8th day of June following any applicable Vesting Date, or the first payroll period on or after the 8th day of December following any applicable Vesting Date.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) under the Company’s 2022 Equity Incentive Plan for no consideration, each RSU deliverable into one share of common stock.
The RSUs vested at issuance on the grant date. Settlement into common shares will occur as soon as practicable after the earlier of the fifth business day following the director’s service ending or the first annual meeting of stockholders following the grant date.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. A Form 4 discloses an award of 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, par value $0.001, and the award was granted for no consideration.
The RSUs vested at issuance on the grant date and will be settled in common stock as soon as practicable after the earlier of (i) the fifth business day following the director’s departure from the Board or (ii) the first annual meeting of stockholders following the grant date. Following the reported transaction, the director holds 74,700 derivative securities on a direct ownership basis.
Cypherpunk Technologies (CYPH)November 11, 2025, the director received 74,700 restricted stock units (RSUs) for no cash consideration under the 2022 Equity Incentive Plan. The RSUs vested at issuance.
Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual stockholder meeting after the grant date.
Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant. A director received 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration, with each RSU settling 1-for-1 into common stock.
The RSUs vested at issuance. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the board or the first annual meeting of stockholders following the grant date. Following the transaction, the filing lists 74,700 derivative securities held direct.
Cypherpunk Technologies Inc. (CYPH) filed a Form 4 reporting an equity grant to a director. On November 11, 2025, the reporting person was awarded 74,700 restricted stock units (RSUs) priced at $0 under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date, with settlement in common stock on a one-for-one basis. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual meeting of stockholders after the grant date, subject to applicable tax withholdings.
Cypherpunk Technologies Inc. (CYPH) reported a director equity award on Form 4. The reporting person received 74,700 restricted stock units (RSUs) on November 11, 2025 at an exercise price of $0, granted under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock on the earlier of the fifth business day after the reporting person ceases to serve on the board or the first annual meeting of stockholders following the grant date. Following the transaction, the reporting person holds 74,700 derivative securities directly.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant on a Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) awarded for $0 under the company’s 2016 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock after the earlier of the fifth business day following the director’s service end or the first annual stockholders’ meeting after the grant. Following the transaction, the reporting person beneficially owned 74,700 derivative securities, held directly.